Submitted by Luciana Ferreira (lucgeral@gmail.com) on 2016-05-20T11:06:25Z No. of bitstreams: 2 Dissertação - Rogerio Coutinho das Neves - 2015.pdf: 6048850 bytes, checksum: 1bac6d1d4aa28a3cf0ebbb228b593986 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2016-05-20T11:12:51Z (GMT) No. of bitstreams: 2 Dissertação - Rogerio Coutinho das Neves - 2015.pdf: 6048850 bytes, checksum: 1bac6d1d4aa28a3cf0ebbb228b593986 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) / Made available in DSpace on 2016-05-20T11:12:51Z (GMT). No. of bitstreams: 2 Dissertação - Rogerio Coutinho das Neves - 2015.pdf: 6048850 bytes, checksum: 1bac6d1d4aa28a3cf0ebbb228b593986 (MD5) license_rdf: 23148 bytes, checksum: 9da0b6dfac957114c6a7714714b86306 (MD5) Previous issue date: 2015-02-27 / Conselho Nacional de Pesquisa e Desenvolvimento Científico e Tecnológico - CNPq / Outbreaks caused by atypical mycobacteria are considered as an emerging problem in Brazil and Goias, being frequently associated with invasive procedures, such as laparoscopy, arthroscopy, and aesthetic surgeries among others. Treatment of mycobacteriosis requires highly toxic drugs with doubtful sterilizing effects. Consequently, several studies aim to search for new drugs or molecules with anti-mycobacterial biological activities. The objective of this study was to prospect biomolecules from the venom of the social wasp Polybia paulista (Vespoidea, Vespidae, Polistinae) and from the Tityus sp scorpion with antimycobacteria activity against Mycobacterium abscessus subsp. bolletii (GO06). Peptides from the wasp and scorpion venoms were evaluated in broth microdilution assay and in macrophage infected cultures to determine minimum inhibitory concentration. Peptides with antimycobacterial activity were further evaluated by scanning electron microscopy of M. abscessus subsp. bolletii treated cultures. The peptide toxicities were evaluated on macrophage cultures. Peptides Agelaia-MP, Polybia-MPII, and AVA, derived from wasp and peptides AMP 1, 2, 4, 6, and 8 derived from scorpion presented antimycobacterial activities. AVA and AMP 4 peptides were not toxic for macrophages. In this work three peptides derived from the wasp venom and five peptides derived from the scorpion venom were identified as having antimycobacterial activity. / Surtos causados por micobactérias atípicas são considerados emergentes no Brasil e em Goiás e têm tem sido associados a procedimentos invasivos, como a laparoscopia, artroscopia e cirurgia estética dentre outros. O tratamento de micobacterioses envolve drogas altamente tóxicas que apresentam efeito esterilizante relativo. Portanto, vários estudos têm como alvo a busca de novas drogas ou moléculas biológicas com atividade micobactericida. O objetivo deste estudo foi prospectar biomoléculas do veneno de vespa social Polybia paulista (Vespoidea, Vespidae, Polistinae) e de escorpiões do gênero Tityus com atividade micobactericida in vitro contra Mycobacterium abscessus subsp. bolletii (GO06). Peptídeos derivados do veneno da vespa e do escorpião foram avaliados por microdiluição em caldo, e em culturas de macrófagos infectados determinando a concentração inibitória mínima. Para os peptídeos com atividade micobactericida, o potencial dano causado à parede celular da micobactéria foi analisado por microscopia eletrônica de varredura. A toxicidade de dois peptídeos com potencial uso farmacológico foram avaliados em culturas de macrófagos peritoneais de camundongos BALB/c. Os peptídeos Agelaia-MP, Polybia-MPII e AVA derivados do veneno da vespa e os peptídeos AMP 1, 2, 4, 6 e 8 derivados do veneno de escorpião apresentaram atividade micobactericida. Os peptídeos micobactericidas agem desestruturando os envoltório das bacilos de M. abscessos subsp. bolletti. Os peptídeos AVA e o AMP 4 não apresentaram toxicidade para culturas de macrófagos, e reduziram a carga bacilar de culturas de macrófagos infectadas com M. abscessus subsp. bolletii. Neste trabalho identificou-se três peptídeos derivados da peçonha de vespa e cinco peptídeos derivados de veneno de escorpião com atividade micobactericida.

Peptídeos antimicrobianos (PAMs) fazem parte de um dos mecanismos da imunidade inata contra infecções. A microplusina é um PAM de 10.204 Da, isolado da hemolinfa livre de células e dos ovos do carrapato Rhipicephalus (Boophilus) microplus. É um PAM aniônico em pH fisiológico, possui seis resíduos de cisteína, com formação de três pontes dissulfeto, além de sete resíduos de histidina concentrados principalmente na sua porção C-terminal. O presente trabalho teve como objetivo investigar o mecanismo de ação antimicrobiana da microplusina. A microplusina recombinante é ativa contra várias bactérias Gram-positivas e fungos, porém não apresenta atividade contra bactérias Gram-negativas. Para avaliar o seu mecanismo de ação, foram utilizados dois modelos: a bactéria Micrococcus luteus e o fungo Cryptococcus neoformans. A microplusina é bacteriostática contra M. luteus e apresenta localização intracelular na bactéria. Além disso, observamos que a microplusina liga cobre e que a adição deste metal ao meio de cultivo reduz sua atividade antibacteriana. Bactérias M. luteus pré-incubadas com microplusina retomam o seu crescimento quando cobre é adicionado ao meio. Estes dados indicam que a atividade da microplusina está relacionada à sua habilidade de depletar cobre do meio extra ou intracelular, sugerindo um efeito nutricional para o peptídeo. A microplusina apresenta estrutura terciária com cinco a-hélices e sua ligação ao cobre não induz mudanças conformacionais. Observou-se que as histidinas 1, 2 e 74 da microplusina podem estar envolvidas na formação de um sítio de ligação ao cobre. Quanto à C. neoformans, verificou-se que a microplusina inibe a melanização do fungo, um fator de virulência catalisado pela lacase, uma enzima cobre-dependente. Entretanto, a microplusina não afeta a atividade da lacase, nem sua expressão gênica. O peptídeo também não inibe a auto-polimerização de substratos fenólicos que levam à melanização. Sendo assim, mais estudos são necessários a fim de avaliar o mecanismo pelo qual a microplusina inibe a melanização. Adicionalmente, a microplusina afeta a viabilidade do fungo e reduz o tamanho de sua cápsula, outro importante fator de virulência. As atividades da microplusina sobre C. neoformans sugerem o seu potencial terapêutico. Experimentos in vivo com modelo murino, mostraram que a microplusina reduz o processo inflamatório e a viabilidade de C. neoformans nos pulmões, indicando que em condições otimizadas, o peptídeo pode atuar no controle de infecções. / Antimicrobial peptides (AMPs) take part of innate immune mechanisms against infections. Microplusin is a 10,204 Da AMP, isolated from cell-free hemolymph and eggs of the tick Rhipicephalus (Boophilus) microplus. It is an anionic AMP at physiological pH, with six cysteine residues forming three disulfide bridges and seven histidine residues clustered mainly at the carboxy end portion. The goal of the present work was investigate the antimicrobial action mechanism of microplusin. Recombinant microplusin is active against Gram-positive bacteria and fungi, however, no activity is detected for Gram-negative bacteria. Two models were used to evaluate the action mechanism of microplusin: the bacteria Micrococcus luteus and the yeast Cryptococcus neoformans. Microplusin is bacteriostatic against M. luteus and its localization is intracellular for these bacteria. Moreover, microplusin binds copper and the addition of this metal into the medium reduces its antibacterial activity. M. luteus bacteria pre-treated with microplusin recover its growth when copper is added. These data indicate that microplusin activity is related to its ability to deplete copper present in the extracellular or intracellular environment, suggesting a nutritional effect. Microplusin presents a tertiary structure with five a-helix and the copper binding does not induce conformation changes. In addition, it was observed that histidines 1, 2 and 74 from microplusin may be involved in the formation of a copper binding site. About C. neoformans, it was verified microplusin inhibits its melanization, a virulence factor catalyzed by laccase, a copper dependent enzyme. However, microplusin does affect neither laccase activity nor its gene expression. The melanization caused by auto-polymerazation of phenolic substrates, is also not inhibited by microplusin. Hence, additional studies are required to evaluate the mechanism by which microplusin inhibits melanization. In addition, microplusin also affects the fungi viability and reduces the capsule size, another important virulence factor.The microplusin activities against C. neoformans suggest its therapeutic potential. In vivo experiments with murine model showed that microplusin reduces the inflammation and the viability of C. neoformans in the lungs, indicating that, in optimized conditions, the peptide may act in the infection control.

Le microbiote humain est constitué de milliers d’espèces bactériennes qui synthétisent de nombreux métabolites secondaires. Cependant, notre connaissance des produits naturels dérivés du microbiome est encore limitée. Parmi eux, les RiPPs (Ribosomally Synthesized and Post-translationally modified Peptides) apparaissent comme une famille majeure de produits naturels possédant diverses structures et fonctions biologiques dont des propriétés antibiotiques, en faisant une famille de molécules d’intérêt majeur pour la santé publique. La biosynthèse des RiPPs commence par la traduction d’un peptide précurseur, qui est ensuite maturé par l’action d’une ou plusieurs enzymes avant l’excision d’une séquence signal et l’export du produit naturel actif. La diversité structurale et fonctionnelle des RiPPs démontre la nécessité de la compréhension des voies de biosynthèse de ces produits naturels, de l’étude systématique des mécanismes de modification et de la caractérisation des maturases associées. En particulier, une famille de métallo-enzymes, les enzymes à radical S-adénosyl-L-méthionine (SAM), a récemment été impliquée dans la biosynthèse de nombreux RiPPs. Ces enzymes catalysent un large éventail de réaction, via un mécanisme de chimie radicalaire, aboutissant à une grande variété de modifications post-traductionnelles. Néanmoins, les voies de biosynthèse de nombreux RiPP restent mal comprises.En 2011, il a été montré que Ruminococcus gnavus, un membre important du microbiote humain, produisait un peptide actif contre Clostridium perfringens, la Ruminococcin C (RumC). Le séquençage de l’opéron de biosynthèse de RumC montre la présence de cinq gènes codants des peptides précurseurs (RumC1-5) et deux gènes codant des enzymes (RumMC1 et RumMC2).L’objectif de ma thèse est de mieux comprendre les voies de biosynthèse des produits naturels au sein du microbiome humain. Nous avons démontré l’appartenance des protéines RumMC1 et RumMC2 à la famille des enzymes à radical SAM, ainsi que leurs implications dans la formation de quatre modifications post-traductionnelles (ponts α-thioether) essentielles à l’activité antibiotique de RumC1 et RumC2. Ces études nous ont permis de proposer un mécanisme catalytique pour la maturation de la Rummonicoccin C et ainsi de mieux documenter cette famille d’enzymes émergentes. / The human microbiota consists of thousands bacterial species which synthesize numerous secondary metabolites. However, our knowledge of microbiome-derived natural products is still limited. Among them, RiPPs (Ribosomally synthesized and Post-translationally modified Peptides) are emerging as a major family of natural products possessing diverse structures and biological functions including antibiotic properties, making them a major family of molecules of interest for public health. The biosynthesis of RiPPs occurred by the translation of a precursor peptide, which is then matured via the action of one or more enzymes before the excision of a signal sequence and the export of the active natural product. The structural and functional diversity of RiPPs demonstrates the need for understanding the biosynthetic pathways of these natural products, the systematic study of the modification mechanisms and the characterization of associated maturases. In particular, a family of metallo-enzymes, the S-adenosyl-L-methionine radical (SAM) enzymes, has recently been implicated in the biosynthesis of many RiPPs. These enzymes catalyze a wide range of reactions, via a mechanism of radical chemistry, resulting in a wide variety of post-translational modifications. Nevertheless, the biosynthetic pathways of many RiPPs remain poorly understood.In 2011, it was shown that Ruminococcus gnavus, a major member of the human microbiota, produced an active peptide against Clostridium perfringens, Ruminococcin C (RumC). Sequencing of the RumC biosynthesis operon shows the presence of five genes encoding precursor peptides (RumC1-5) and two genes encoding enzymes (RumMC1 and RumMC2).The aim of my thesis is to understand the biosynthetic pathways of natural products within the human microbiome. We have demonstrated that the RumMC1 and RumMC2 proteins belong to the radial SAM enzyme family, as well as their involvement in the formation of four post-translational modifications (α-thiother bridges) essential for the antibiotic activity of RumC1 and RumC2. These studies allowed us to propose a catalytic mechanism for the maturation of Rummonicoccin and thus to better document this family of emerging enzymes.

Proline-rich antimicrobial peptides (PrAMPs) are promising candidates for the treatment of infections caused by highpriority human pathogens. Their mode of action consists of (I) passive diffusion across the outer membrane, (II) active transport through the inner membrane, and (III) inhibition of protein biosynthesis by blocking the exit tunnel of the 70S ribosome. We tested whether in vitro data on ribosomal binding and bacterial uptake could predict the antibacterial activity of PrAMPs against Gram-negative and Gram-positive bacteria. Ribosomal binding and bacterial uptake rates were measured for 47 derivatives of PrAMP Onc112 and compared to the minimal inhibitory concentrations (MIC) of each peptide. Ribosomal binding was evaluated for ribosome extracts from four Gram-negative bacteria. Bacterial uptake was assessed by quantifying each peptide in the supernatants of bacterial cultures. Oncocin analogues with a higher net positive charge appeared to be more active, although their ribosome binding and uptake rates were not necessarily better than for Onc112. The data suggest a complex mode of action influenced by further factors improving or reducing the antibacterial activity, including diffusion through membranes, transport mechanism, secondary targets, off-target binding, intracellular distribution, and membrane effects. Relying only on in vitro binding and uptake data may not be sufficient for the rational development of more active analogues.

In view of the global spread of multiresistant bacteria and the occurrence of panresistant bacteria, there is an urgent need for antimicrobials with novel modes of action. A promising class is antimicrobial peptides (AMPs), including them proline-rich AMPs (PrAMPs), which target the 70S ribosome to inhibit protein translation. Here, we present a new designer peptide, Api805, combining the N- and C-terminal sequences of PrAMPs Api137 and drosocin, respectively. Api805 was similarly active against two Escherichia coli B strains but was inactive against E. coli K12 strain BW25113. These different activities could not be explained by the dissociation constants measured for 70S ribosome preparations from E. coli K12 and B strains. Mutations in the SbmA transporter that PrAMPs use to pass the inner membrane or proteolytic degradation of Api805 by lysate proteases could not explain this either. Interestingly, Api805 seems not to bind to the known binding sites of PrAMPs at the 70S ribosome and inhibited in vitro protein translation, independent of release factors, most likely using a “multimodal effect”. Interestingly, Api805 entered the E. coli B strain Rosetta faster and at larger quantities than the E. coli K-12 strain BW25113, which may be related to the different LPS core structure. In conclusion, slight structural changes in PrAMPs significantly altered their binding sites and mechanisms of action, allowing for the design of different antibiotic classes.

No description available.

The growing problem of antibiotic resistance and the lack of promising prospective antibiotics have forced us to search for new classes of antibiotics. Among the candidates to develop into future antibacterials are antimicrobial peptides (AMPs). These potent, broad spectrum compounds are important components of innate immunity of organism from all kingdoms of life. One such family of mini-proteins from plants is called cyclotides, whose members are defines by cyclic backbone and a cystine knot (CCK), which confers to them extreme stability in the face of biological, chemical and physical insults.     Some cyclotides possess Gram-negative specific antibacterial activity; the purpose of this thesis was to characterize how these molecules kill bacteria, and how bacteria would respond to treatment with cyclotides. For this purpose, Salmonella enterica and Escherichia coli mutants resistant to the cyclotides cycloviolacin O2 and cycloviolacin O19, respectively, were selected. These mutants were characterized by whole genome sequencing, genetic reconstitution, fitness measurements, and cross-resistance studies. These studies identified a number of genetic pathways for resistance development to cyclotides. These mutants displayed variable fitness profiles in laboratory growth media and in mice competition experiments, with some mutants possessing a fitness advantage in mice. Cross-resistance studies resulted in the identification of several cases of cross-resistance and collateral sensitivity between cyclotides and other AMPs/antibiotics.      Antimicrobial effects of cyclotides were assayed in different conditions and in bacterial organisms with different surface characteristics. In addition, immunolocalization experiments were performed to explore the biological distribution of cyclotides in plants and to determine the mechanism of action of cyclotides in bacteria, respectively. Antibodies raised against cyO2 were used for this purpose. Immunohistochemical techniques applied to plant cells, tissues and organs provided the information that cyclotides were distributed in all plant organs, and were found in tissues vulnerable to pathogen attack, and that cyclotides were stored in the vacuoles of plant cells. Immunogold staining of cyclotide treated cells of S. typhimurium, showed effects of cyclotide treatment on the cell envelope components as well as cytoplasm. A higher number of cyclotide molecules was associated with the cell envelope, but a considerable fraction of them penetrated into the cytoplasm.

Drosophila melanogaster has been integral to unravelling the mechanisms of animalian immunity. Diverse species of Drosophila with sequenced genomes have been used to characterize how immune systems respond to natural selection. However, Drosophila is an incredibly speciose lineage, especially so in the subgenus Drosophila. Of the 12 genomes sequenced in 2007, ushering in the era of Drosophila comparative genomics, only three were subgenus Drosophila flies, and none were from the lesser- characterized Immigrans-Tripunctata clade. Recently, multiple Immigrans-Tripunctata clade Drosophila have been sequenced, including the transcriptome of Drosophila neotestacea. I investigated the realized immune responses of D. neotestacea to characterize the immune repertoire of this divergent lineage. The signalling pathways of D. neotestacea were largely conserved, though there were interesting patterns of evolution in antimicrobial peptide genes (AMPs). One of these AMPs, a diptericin, was highly dissimilar to diptericins in D. melanogaster, and conserved in other subgenus Drosophila flies. This prompted me to characterize the evolution of the diptericin gene family in Drosophila. I found that Drosophila diptericins have evolved under positive selection, and display intriguing differences in net charge to well-conserved diptericin domains. I assessed the expression profile of this divergent D. neotestacea diptericin, and found that it did not respond to Serratia bacterial challenge, unlike diptericin in D. melanogaster. I also highlight a potential novel drosocin-like AMP conserved throughout the subgenus Drosophila. These results agree that signalling pathways are highly conserved in diverse insects, including Drosophila. However seemingly-conserved effectors of the Drosophila immune response (such as AMPs) may have previously unappreciated variation in expression and function. / Graduate / 0718 / 0353 / 0369 / markhans@uvic.ca

O melanoma cutâneo é a neoplasia de pele de maior mortalidade e grande imprevisibilidade na sua evolução. Na doença disseminada, as opções terapêuticas são pouco eficazes. A pesquisa de novos marcadores tumorais permite a melhor compreensão da patogênese do melanoma e possibilita a descoberta de alvos moleculares. A proteína Dermicidina (DCD) foi identificada entre os 9 genes de uma assinatura gênica de predição de diagnóstico clínico do melanoma humano, porém vários autores divergem sobre o papel desta na doença e os mecanismos moleculares pelos quais a DCD atua nos tumores permanecem incertos. O presente estudo teve como objetivo investigar o papel da DCD na tumorigênese do melanoma maligno e correlacionar sua expressão com dados clínicos, demográficos e patológicos dos pacientes. Através da técnica de imuno-histoquímica em lâminas de TMAs (tissue-microarray), o padrão de expressão de DCD foi analisado em tecido tumoral de duas coortes de pacientes, a primeira com 53 casos tratados no Hospital A.C. Camargo, predominantemente caucasianos, e a segunda com 48 casos, todos asiáticos, obtidos comercialmente da empresa IMGENEX. A análise in situ da Dermicidina mostrou que a proteína está expressa de forma heterogênea nas células tumorais, e pode ocorrer tanto em tumores amelanocíticos como melanocíticos. Em melanomas primários, a expressão de DCD foi mais frequente em tumores localizados nas regiões do tronco e membros superiores, já nas metástases, a proteína foi detectada predominantemente em células em transito nos linfonodos (69,23% dos casos). Analisando os resultados dos 101 pacientes das duas coortes em conjunto, pelo método de Kaplan-Meier, foi confirmado que nos indivíduos com tumores DCD-negativo, a taxa de sobrevida foi de 65,54% em 60 meses, e de 62,86% em 130 meses. Já indivíduos com tumor DCD-positivo tiveram sobrevida de 43,33% em 5 anos, e 28,12% em 130 meses, sendo a diferença significante entre os grupos (p=0,0229). A taxa de óbito dos pacientes com tumor DCD-positivo foi mais elevada, 56%, quando comparada à taxa dos indivíduos com tumor DCDnegativo, 33,33% (p=0,0281). Também foi encontrada uma tendência de tumores expressando DCD se relacionarem a pacientes com idade superior a 50 anos (p=0,1057). Em uma consulta de 4 estudos diferentes que reuniram os dados de sequenciamento de DNA de tumores de 515 pacientes, observamos que o gene DCD, em melanomas, não se encontra predominantemente amplificado, mas sim mutado. A substituição E43K foi a alteração mais frequente, correspondendo a 70% dos casos com mutação no gene. Ao relacionarmos os casos disponíveis de mutação em DCD com os genes BRAF, NRAS, MITF, CDKN2A e ERBB4, encontrou-se uma associação com a mutação BRAF V600E nos casos em que ocorria a mutação DCD E43K. Por ter alta frequência em melanomas (variando entre 45 e 54%), e ser um indicador de pior prognóstico para a neoplasia, a expressão de DCD pode ser considerada um potencial biomarcador / Cutaneous melanoma is the skin neoplasia with the highest mortality rate and great unpredictability in its evolution. In disseminated disease, the treatment options are little effective. The research for new tumor markers allows a better understanding of the pathogenesis of melanoma and enables the discovery of molecular targets. The Dermcidin protein (DCD) was identified among the nine genes of a gene signature predicting clinical diagnosis of human melanoma, although many authors differ on its role in the disease and the molecular mechanisms by which DCD acts in tumors remain unclear. The present study aimed to investigate the role of DCD in the tumorigenesis of malignant melanoma and to correlate its expression with clinical, demographic and pathologic data of patients. Using the technique of immunohistochemistry in TMA slides (tissue microarray), the expression pattern of DCD was analyzed in tumoral tissue of two cohorts of patients, the first with 53 cases treated in hospital AC Camargo, predominantly caucasians, and the second with 48 cases, all Asians, commercially obtained from IMGENEX company. The in situ analysis of Dermcidin showed that the protein is expressed in a heterogeneous manner in tumor cells, and can occur in non-melanocytic as well as in melanocytic tumors. In the primary melanoma, DCD expression was more seen in tumors located in the regions of torso and upper limbs. In the metastases, the protein was found predominantly in cells in transit in the lymph nodes (69.23% of cases). Analyzing the 101 patients of the two cohorts together, by the Kaplan-Meier method, it was confirmed that patients with DCD-negative, the survival rate was 65.54% in 60 months, and 62.86% in 130 months, while the group of patients with DCD-positive tumor had 43.33% in 5 years, and 22.12% in 130 months, knowing that a difference between the groups was significative (p=0.0229). The death rate of patients with DCD-positive tumor was higher, 56%, when compared with the death rate of individuals with DCD-negative tumor, 33.33% (p=0.0281). It was also found a trend of tumors expressing DCD related to patients older than 50 years (p=0.1057). In a search of 4 different studies grouping the DNA sequencing tumor of 515 patients we observed that the DCD gene, in melanoma, is not predominantly amplified, but mutated. The E43K substitution was the most frequent alteration, corresponding to 70% of cases of gene mutation. When comparing the available cases of mutations in DCD with the genes BRAF, NRAS, MITF, CDKN2A, ERBB4, we found an association with the BRAF V600E mutation in cases where occurred the DCD E43K. By having high frequency in melanomas (ranging between 45 and 54%) and being an indicator of poor prognosis for the neoplasia, DCD expression can be considered as a potential biomarker

A hemoglobina (Hb) é uma fonte reconhecida de peptídeos com funções biológicas diversas. O fragmento 33-61 da cadeia α da Hb, isolado do trato gastrointestinal do carrapato Boophilus microplus, foi o primeiro a ser descrito com ação antimicrobiana. O seu análogo sintético amidado, Hb33-61a, mostrou-se ativo contra bactérias Gram-positivas e fungos [Fogaça et al. (1999) J. Biol. Chem. 274, 25330-4]. O estudo de análogos do Hb33-61 nas formas amidada e com carboxila livre revelou que a amidação provoca aumento significativo da atividade frente a Candida albicans. Por apresentar propriedades biológicas e estruturais idênticas às do Hb33-61a, o Hb40-61a pareceu ser a sua porção mÌnima ativa [Sforça et al. (2005) Biochemistry 44, 6440- 51; Machado et al. (2007) Biopolymers 88, 413-26]. Para comprovar tal sugestão, no presente trabalho, sintetizamos, purificamos e caracterizamos novos an·logos do Hb33-61a, bem como os avaliamos quanto às suas atividades frente a C. albicans e Micrococcus luteus. Os resultados confirmaram a sugestão apenas para a ação antifúngica. O análogo Hb40-61a também se mostrou ativo frente a C. albicans resistente a fluconazol. A sua atividade antifúngica se mostrou fortemente dependente da força iônica do meio. A sua baixa atividade hemolítica foi confirmada mesmo em meio de baixa força iônica. O peptídeo Hb40-61a não apresentou sinergismo com o fluconazol frente a C. albicans. A cinética de morte celular mostrou que ele mata a levedura de forma rápida. Portanto, esta hemocidina sintética pode apresentar valor comercial se a via de administração for tópica ou se o seu uso envolver meios de baixa força iônica. Além disso, ela é um modelo valioso para o estudo do mecanismo de ação de peptídeos antimicrobianos com características estruturais similares e pode servir de base para o desenho de novos agentes antibiôticos. / It is well known that hemoglobin (Hb) is a source of biologically active peptides. The fragment 33-61 of bovine hemoglobin α-chain, isolated from the gut contents of the tick Boophilus microplus, was the first identified with antimicrobial activity . Its amidated analogue, Hb33-61a, showed to be active against Gram-positive bacteria and fungi strains [FogaÁa et al. (1999) J. Biol. Chem. 274, 25330-4]. The study of a series of carboxyl-free and amidated synthetic analogues of Hb33-61 revealed that C-terminus amidation enhances the activity against Candida albicans. Since Hb33-61a and Hb40-61a presented identical biological and structural properties, it seemed that Hb40-61a was Hb33-61a minimal active motif [SforÁa et al. (2005) Biochemistry 44, 6440- To test this suggestion, in the present study 51; Machado et al. (2007) Biopolymers 88, 413-26]. we synthesized, purified and characterized Hb40-61a analogues and assayed them against C. albicans and Micrococcus luteus. The results confirmed the suggestion only for the antifungal activity. When tested against fluconazole-resistant C. albicans, Hb40-61a was also active. Its antifungal activity showed to be dependent on the ionic strength of the medium. Its low hemolytic activity was confirmed even under low ionic strength conditions. Hb40-61a had no synergic effect with fluconazole on C. albicans. In vitro time-kill assays demonstrated that Hb40-61a kills the yeast rapidly. Therefore, this synthetic hemocidin may be of commercial interest for topical application or other uses involving low ionic strength medium. Moreover, it can serve as a template for the study of the mechanism of action of structurally related antimicrobial peptides or for the design of novel antibiotic drugs.